Sullivan & Cromwell has advised Japan's Sumitomo Pharma and its subsidiary Sumitovant on the $1.7 billion purchase of the remaining shares of Swiss pharmaceutical company Myovant Sciences, which was represented by Skadden, Arps, Slate, Meagher & Flom.